-transparent.png){kind=logo}
Circulating stem cells exist in sufficient numbers in mouse, dog, and man to allow collection and transplantation after ablative treatment. Preclinical studies in the mouse have shown a low concentration, with a transplantation potential ratio of bone marrow to blood of 1:100. The ratio of circulating stem cells to bone marrow stem cells is more favorable in the dog (1:10-20). Recent pilot studies carried out in different centers with 10 patients have shown that this approach is feasible in man, too. It appears that 5 X 10(8) mononuclear cells/kg of body weight collected by seven or eight leukapheresis procedures of about 4 hrs each is sufficient for fast hemopoietic recovery after marrow ablative treatment. Potential advantages of the use of blood stem cells over bone marrow stem cells are the decreased likelihood of contamination with malignant cells, the avoidance of general anesthesia, and the infusion of immunocompetent cells, which might hasten immunorecovery in the autologous setting.
A R Zander, and
K J Cockerill
January 1990,
Bone marrow transplantation,
A R Zander, and
K J Cockerill
January 1994,
Duodecim; laaketieteellinen aikakauskirja,
A R Zander, and
K J Cockerill
January 1989,
Ugeskrift for laeger,
A R Zander, and
K J Cockerill
March 2005,
Medical science monitor : international medical journal of experimental and clinical research,
A R Zander, and
K J Cockerill
January 1999,
Przeglad lekarski,
A R Zander, and
K J Cockerill
August 2000,
Current rheumatology reports,
A R Zander, and
K J Cockerill
January 1980,
Haematology and blood transfusion,
A R Zander, and
K J Cockerill
March 1997,
Casopis lekaru ceskych,
A R Zander, and
K J Cockerill
March 1999,
Leukemia research,
A R Zander, and
K J Cockerill
January 1982,
Experimental hematology,
